BRPI0517091B8 - composto 4-hidroxibenzomorfano substituído na posição-3 por carboxamida ou tiocarboxamida - Google Patents

composto 4-hidroxibenzomorfano substituído na posição-3 por carboxamida ou tiocarboxamida

Info

Publication number
BRPI0517091B8
BRPI0517091B8 BRPI0517091A BRPI0517091A BRPI0517091B8 BR PI0517091 B8 BRPI0517091 B8 BR PI0517091B8 BR PI0517091 A BRPI0517091 A BR PI0517091A BR PI0517091 A BRPI0517091 A BR PI0517091A BR PI0517091 B8 BRPI0517091 B8 BR PI0517091B8
Authority
BR
Brazil
Prior art keywords
thiocarboxamide
compound
carboxamide
hydroxybenzomorphan
substituted
Prior art date
Application number
BRPI0517091A
Other languages
English (en)
Portuguese (pt)
Inventor
P Wentland Mark
Original Assignee
Rensselaer Polytech Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rensselaer Polytech Inst filed Critical Rensselaer Polytech Inst
Publication of BRPI0517091A publication Critical patent/BRPI0517091A/pt
Publication of BRPI0517091B1 publication Critical patent/BRPI0517091B1/pt
Publication of BRPI0517091B8 publication Critical patent/BRPI0517091B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/26—Benzomorphans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
BRPI0517091A 2004-11-05 2005-11-03 composto 4-hidroxibenzomorfano substituído na posição-3 por carboxamida ou tiocarboxamida BRPI0517091B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62534804P 2004-11-05 2004-11-05
US60/625,348 2004-11-05
PCT/US2005/039911 WO2006052710A1 (en) 2004-11-05 2005-11-03 4-hydroxybenzomorphans

Publications (3)

Publication Number Publication Date
BRPI0517091A BRPI0517091A (pt) 2008-09-30
BRPI0517091B1 BRPI0517091B1 (pt) 2019-10-08
BRPI0517091B8 true BRPI0517091B8 (pt) 2021-05-25

Family

ID=36128632

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517091A BRPI0517091B8 (pt) 2004-11-05 2005-11-03 composto 4-hidroxibenzomorfano substituído na posição-3 por carboxamida ou tiocarboxamida

Country Status (20)

Country Link
US (7) US7262298B2 (enExample)
EP (2) EP1817291A1 (enExample)
JP (3) JP5198067B2 (enExample)
KR (1) KR101115841B1 (enExample)
CN (1) CN101090891B (enExample)
AT (1) ATE557006T1 (enExample)
AU (1) AU2005304950B2 (enExample)
BR (1) BRPI0517091B8 (enExample)
CA (1) CA2587074C (enExample)
CY (1) CY1112946T1 (enExample)
DK (1) DK2251330T3 (enExample)
ES (1) ES2387737T3 (enExample)
IL (1) IL182983A (enExample)
MX (1) MX2007005389A (enExample)
NO (1) NO340204B1 (enExample)
PL (1) PL2251330T3 (enExample)
PT (1) PT2251330E (enExample)
RU (2) RU2480455C2 (enExample)
SI (1) SI2251330T1 (enExample)
WO (1) WO2006052710A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4340437B2 (ja) * 2000-10-31 2009-10-07 レンセラール ポリテクニック インスティチュート ８−カルボキサミド−２，６−メタノ−３−ベンズアゾシン
KR101115841B1 (ko) * 2004-11-05 2012-03-09 렌슬러 폴리테크닉 인스티튜트 4-하이드록시벤조모르판
US7557119B2 (en) 2005-07-21 2009-07-07 Rensselaer Polytechnic Institute Large substituent, non-phenolic opioids
DE602008004245D1 (de) 2007-05-04 2011-02-10 Mallinckrodt Inc Verbessertes verfahren zur herstellung von 6-alpha-hydroxy-n-alkylierten opiaten
JP2010533719A (ja) 2007-07-17 2010-10-28 マリンクロッド・インコーポレイテッド 還元的アミノ化によるｎ−アルキル化オピエートの調製
CA2694497C (en) 2007-08-09 2016-07-12 Rensselaer Polytechnic Institute Quaternary opioid carboxamides
NZ592005A (en) 2008-09-30 2013-03-28 Mallinckrodt Llc Process for the preparation of a N-alkylated ketomorphinan by selective catalytiC hydrogen transfer reduction
US8946419B2 (en) 2009-02-23 2015-02-03 Mallinckrodt Llc (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
CA2754984C (en) * 2009-03-19 2018-06-26 Alkermes, Inc. Morphinan derivatives with high oral bioavailability
US20100261906A1 (en) * 2009-04-09 2010-10-14 Mallinckrodt Inc. Preparation of 6-Keto, 3-Alkoxy Morphinans
EP2440561B1 (en) 2009-06-11 2014-04-30 Mallinckrodt LLC Reductive amination of 6-keto normorphinans by catalytic hydrogen transfer
PL2440562T3 (pl) 2009-06-11 2017-07-31 Mallinckrodt Llc Otrzymywanie 6-alfa-amino-N-podstawionych morfinanów w wyniku katalitycznego przeniesienia wodoru
SMT201900357T1 (it) * 2009-12-04 2019-07-11 Alkermes Pharma Ireland Ltd Derivati di morfinano per trattamento di abuso di sostanze stupefacenti
CA2793725C (en) 2010-03-22 2018-05-01 Rensselaer Polytechnic Institute Carboxamide bioisosteres of opiates
US8563725B2 (en) 2010-04-29 2013-10-22 Mallinckrodt Llc Preparation of saturated ketone morphinan compounds having low metal content
NZ605234A (en) 2010-07-08 2015-02-27 Alkermes Pharma Ireland Ltd Process for the synthesis of substituted morphinans
SI2608670T1 (sl) 2010-08-23 2019-04-30 Alkermes Pharma Ireland Limited Postopki za zdravljenje pridobivanja teže, ki je posledica uporabe antipsihotičnih zdravil
WO2012138888A1 (en) 2011-04-05 2012-10-11 Alkermes, Inc. Process for the synthesis of quaternary amine compounds
JP2014516085A (ja) 2011-06-09 2014-07-07 マリンクロッド エルエルシー 触媒的水素移動による６−ケトモルフィナンの還元的アミノ化
LT2725908T (lt) 2011-06-29 2017-09-11 Alkermes, Inc. Periferinio poveikio opioidų junginiai
AU2012304484B2 (en) 2011-09-08 2016-07-28 SpecGx LLC Production of alkaloids without the isolation of intermediates
AU2012351806C1 (en) 2011-12-15 2016-06-16 Alkermes Pharma Ireland Limited Compositions of buprenorphine and mu-opioid receptor antagonists
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
NZ631018A (en) 2013-05-24 2017-12-22 Alkermes Pharma Ireland Ltd Morphan and morphinan analogues, and methods of use
EP3003311A2 (en) 2013-05-24 2016-04-13 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
RU2761219C2 (ru) * 2017-03-02 2021-12-06 Убе Индастриз, Лтд Терапевтическое средство от расстройств, связанных с употреблением алкоголя
CN107089948B (zh) * 2017-04-28 2020-07-17 云南大学 吗吩衍生物及其制备方法和应用
CN111978252A (zh) * 2019-05-21 2020-11-24 复旦大学 手性苯并吗吩烷类衍生物及其制备方法和在药学上的应用
TW202140009A (zh) * 2020-02-13 2021-11-01 大陸商上海翰森生物醫藥科技有限公司 ３－甲醯胺基－４－羥基納曲酮氘代衍生物、其製備方法及其在醫藥上的應用
CN111205151B (zh) * 2020-02-29 2021-03-05 深圳市祥根生物科技有限公司 一种布洛芬杂质i的环保制备方法
WO2022101444A1 (en) 2020-11-12 2022-05-19 Alkermes Pharma Ireland Limited Immediate release multilayer tablet
CN114621238A (zh) * 2020-12-10 2022-06-14 鲁南制药集团股份有限公司 一种制备纳呋拉啡的方法
KR102663533B1 (ko) * 2021-11-09 2024-05-08 백미선 레이저 치료기기용 온냉각장치

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032529A (en) 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
US3957793A (en) 1974-09-20 1976-05-18 Sterling Drug Inc. Hydroxyiminobenzazocines
SU635868A3 (ru) * 1974-11-12 1978-11-30 Бристол Мейерз Компани (Фирма) Способ получени морфиновых производных или их солей
US4205171A (en) 1976-01-12 1980-05-27 Sterling Drug Inc. Aminomethanobenzazocines and nitromethanobenzazocines
US4373139A (en) 1979-04-30 1983-02-08 Motorola, Inc. Detectors
US4649200A (en) 1986-05-08 1987-03-10 Regents Of The University Of Minnesota Substituted pyrroles with opioid receptor activity
EP0632041A1 (en) 1993-07-01 1995-01-04 Katholieke Universiteit Nijmegen New morphine derivatives having improved analgesic and narcotic properties
JP2000503019A (ja) 1996-01-10 2000-03-14 スミスクライン・ビーチャム・ソシエタ・ペル・アチオニ 複素環縮合モルフィノイド誘導体（ｉｉ）
JP4340437B2 (ja) * 2000-10-31 2009-10-07 レンセラール ポリテクニック インスティチュート ８−カルボキサミド−２，６−メタノ−３−ベンズアゾシン
AU2003281060A1 (en) 2002-07-16 2004-02-02 Rensselaer Polytechnic Institute Process for conversion of phenols to carboxamides via the succinimide esters
KR101115841B1 (ko) * 2004-11-05 2012-03-09 렌슬러 폴리테크닉 인스티튜트 4-하이드록시벤조모르판

Also Published As

Publication number Publication date
KR20070085723A (ko) 2007-08-27
SI2251330T1 (sl) 2012-09-28
CA2587074C (en) 2012-09-04
RU2007120759A (ru) 2008-12-10
US7262298B2 (en) 2007-08-28
US20130231361A1 (en) 2013-09-05
CA2587074A1 (en) 2006-05-18
AU2005304950A1 (en) 2006-05-18
PL2251330T3 (pl) 2012-12-31
IL182983A0 (en) 2007-08-19
RU2010147915A (ru) 2012-05-27
US20140148475A1 (en) 2014-05-29
JP5198067B2 (ja) 2013-05-15
PT2251330E (pt) 2012-07-20
NO20072839L (no) 2007-08-03
JP2008519035A (ja) 2008-06-05
WO2006052710A1 (en) 2006-05-18
CN101090891A (zh) 2007-12-19
JP2013067636A (ja) 2013-04-18
JP2016020364A (ja) 2016-02-04
KR101115841B1 (ko) 2012-03-09
DK2251330T3 (da) 2012-08-06
CN101090891B (zh) 2012-08-01
ATE557006T1 (de) 2012-05-15
AU2005304950B2 (en) 2010-12-09
MX2007005389A (es) 2007-12-07
NO340204B1 (no) 2017-03-20
EP2251330B1 (en) 2012-05-09
US20160075658A1 (en) 2016-03-17
BRPI0517091A (pt) 2008-09-30
US8802655B2 (en) 2014-08-12
US8680112B2 (en) 2014-03-25
ES2387737T3 (es) 2012-10-01
IL182983A (en) 2012-06-28
EP2251330A1 (en) 2010-11-17
CY1112946T1 (el) 2016-04-13
JP6058981B2 (ja) 2017-01-11
US20240092740A1 (en) 2024-03-21
RU2415131C2 (ru) 2011-03-27
US20070238748A1 (en) 2007-10-11
EP1817291A1 (en) 2007-08-15
US20060111384A1 (en) 2006-05-25
US20150011768A1 (en) 2015-01-08
RU2480455C2 (ru) 2013-04-27
BRPI0517091B1 (pt) 2019-10-08

Similar Documents

Publication Publication Date Title
BRPI0517091B8 (pt) composto 4-hidroxibenzomorfano substituído na posição-3 por carboxamida ou tiocarboxamida
BRPI0408247A (pt) usos de antagonistas e agonistas de il-23 e reagentes relacionados
ECSP088461A (es) Composiciones farmacéuticas que contienen buprenorfina
EP1809280A4 (en) MITOTIC KINESINE INHIBITORS AND METHOD OF USE THEREOF
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
BRPI0510777A (pt) indazóis substituìdos, composições que os contêm, processo de produção e utilização
ATE469895T1 (de) Cgrp-rezeptorantagonisten
MY149803A (en) Markup based extensibility for user interfaces
MX358592B (es) Método para formulación de fármaco basado en el aumento de la afinidad de superficies de micropartículas cristalinas hacia agentes activos.
MX2007012237A (es) Amilina y agonistas de amilina para tratar enfermedades y trastornos siquiatricos.
IL189948A0 (en) Y2 selective receptor agonists for therapeutic interventions
BRPI0516727A (pt) métodos para tratar um linfoma positivo em cd30 , para inibir o crescimento de uma célula que expressa cd30, e para tratar ou prevenir uma doença
BRPI0416534A (pt) composições multiparticuladas com estabilidade melhorada
DE60334379D1 (de) Copolymerverbindung, diese enthaltende polymerzusammensetzung, bilderzeugungsverfahren und dieselbe benutzende bilderzeugungsvorrichtung
BRPI0718469A2 (pt) Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto.
UA88308C2 (ru) Агент образования олеогеля, который содержит тритерпен, олеогель и способ его получения
DK1220852T3 (da) Substituerede diazepaner
FR2886851B1 (fr) Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
BRPI0514074A (pt) aperfeiçoamentos em composições em bloco para lavatório
FR2886852B1 (fr) Composition a base d'une avermectine et d'hydrocortisone notamment pour le traitement de la rosacee
PT1713438E (pt) Sabonete medicinal
BRPI0511550A (pt) processamento de ação de interface de usuário utilizando um status de novidade
BRPI0414423A (pt) inibidores de pace4, suas composições farmacêuticas e respectivos usos
ECSP055917A (es) Derivados de diazepanes útiles como inhibidores de lfa
ITBO20040403A1 (it) Riduttore di velocita', particolarmente per estrusori, e simili

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/10/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/10/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/11/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed